Alpha Crest Capital Management LLC Mirati Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$39.16 - $88.71 $290,410 - $657,873	-7,416 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $152,474 - $303,600	2,011 Added 37.21%	7,416 $610,000
Q4 2021 Feb 09, 2022	BUY	$132.01 - $190.29 $713,514 - $1.03 Million	5,405 New	5,405 $793,000
Q3 2021 Nov 10, 2021	SELL	$132.13 - $177.45 $502,094 - $674,310	-3,800 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$144.0 - $179.73 $184,896 - $230,773	-1,284 Reduced 25.26%	3,800 $614,000
Q1 2021 May 13, 2021	BUY	$158.92 - $221.61 $521,893 - $727,767	3,284 Added 182.44%	5,084 $871,000
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $291,690 - $432,486	1,800 New	1,800 $395,000
Q2 2020 Aug 12, 2020	SELL	$72.01 - $120.39 $237,633 - $397,287	-3,300 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $230,274 - $383,493	3,300 New	3,300 $254,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.